Switch RPV-TDF-FTC from NVP-Based Regimen

Near-Rwanda Trial

Switch to RPV-TDF-FTC from NVP-Based Regimen Near-Rwanda: Study Design

- **Background**: Randomized, open-label, single-center, noninferiority study conducted in Rwanda to evaluate a switch from a nevirapine (NVP)-based regimen to a single tablet regimen of rilpivirine-tenofovir DF-emtricitabine (RPV-TDF-FTC)
- **Inclusion Criteria (n = 150 enrolled)**
  - Rwandan adults with HIV-1 infection
  - HIV RNA <50 copies/mL within 12 months of screening
  - HIV RNA <50 copies/mL at screening visit
  - On NVP + lamivudine + 2nd NRTI ≥12 months
  - No prior virologic failure
  - No prior ART change except NRTI substitution
  - eGFR >60 mL/min and Hemoglobin >8 g/dL
  - No active TB or pregnancy
- **Treatment Arms (2:1 randomization)**
  - Continue NVP + 2 NRTIs
  - Switch to RPV-FTC-TDF



Source: Collins SE, et al. Open Forum Infect Dis. 2016;3:ofw141.

Switch to RPV-TDF-FTC from NVP-Based Regimen Near-Rwanda: Results

24 Week Virologic Response (FDA Snapshot Analysis)



Source: Collins SE, et al. Open Forum Infect Dis. 2016;3:ofw141.

Switch to RPV-TDF-FTC from NVP-Based Regimen Near-Rwanda: Results

Week 24: Change in Plasma Lipids from Baseline



Source: Collins SE, et al. Open Forum Infect Dis. 2016;3:ofw141.

Switch to RPV-TDF-FTC from NVP-Based Regimen Near-Rwanda: Conclusions

Conclusions: “A switch from nevirapine-based ART to rilpivirine-emtricitabine-tenofovir disoproxil fumarate had similar virologic efficacy to continued nevirapine-based antiretroviral therapy after 24 weeks with few adverse events.”

Source: Collins SE, et al. Open Forum Infect Dis. 2016;3:ofw141.

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

AETC AIDS Education & Training Center Program

National HIV Curriculum

IDEA INFECTIOUS DISEASES EDUCATION & ASSESSMENT